Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Why body size can relate to both melanoma growth and immune treatment response
Review or Meta-AnalysisTracked over timeA melanoma review links higher body mass index to longer survival during checkpoint inhibitor treatment and examines how fat may also support tumor growth.
-
Evidence date ·Why did body size seem to matter differently during cancer immunotherapy?
Review or Meta-AnalysisTracked over timeA 2021 review found longer survival with higher BMI in some kidney and lung cancer cohorts, but no clear pattern overall. BMI cannot show muscle and fat composition.
-
Evidence date ·What does “drug-related” mean in cancer trial safety reports?
Review or Meta-AnalysisAcross 60 cancer trials, the median incidence of events labeled drug-related in placebo groups was 49%; 40 reports lacked complete attribution data.
-
Evidence date ·What might liposome carriers add to melanoma treatment?
Review or Meta-AnalysisLiposomes may carry drugs or therapeutic genes to melanoma tumors. A 2021 review asks whether this delivery approach could help address treatment resistance.
-
Evidence date ·Why vaccine reactions and immune complications need separate attention during checkpoint therapy
Review or Meta-AnalysisTracked over timeAcross 28 studies, flu and COVID vaccines were generally safe during checkpoint therapy; one cohort saw more mild-to-moderate events but similar severe-event rates.
-
Evidence date ·What did flu shot safety studies find during cancer immunotherapy?
Review or Meta-AnalysisTracked over timePooled studies found no clear difference in death or immune-related side effects between patients who did and did not get a flu shot during checkpoint therapy.
-
Evidence date ·Can a vaccine prompt antibodies during checkpoint cancer treatment?
Review or Meta-AnalysisTracked over timeA 2021 review reported antibody responses to vaccination during checkpoint cancer treatment and raised concern about possible immune-related side effects.
-
Evidence date ·Thyroid treatment preceded an adrenal crisis after cancer immunotherapy
Review or Meta-AnalysisTracked over timeA patient grew sicker after thyroid replacement; low cortisol and ACTH pointed to adrenal insufficiency, while topical steroids and immunotherapy remained possible causes.
-
Evidence date ·Which hormone problems can arise during cancer immunotherapy?
Review or Meta-AnalysisTracked over timeCheckpoint inhibitors most often affect the thyroid and pituitary, but a 2022 review also describes rarer adrenal insufficiency and insulin-deficient diabetes.
-
Evidence date ·Why cancer immunotherapy can affect the thyroid and pituitary in ways that are hard to recognize
Review or Meta-AnalysisTracked over timeA 2021 review explains why thyroid and pituitary problems during checkpoint therapy can be hard to spot, and why screening for adrenal and pituitary disease is debated.